Consistent with these findings, here we showed that p38 MAPK inhibitor SB203058 decreased the expression of cardiac hypertrophy markers ANP and BNP, while their levels were increased by HDAC8 overexpression. The gene discussed is NPPA; the disease is cardiac hypertrophy.